尿激酶与链激酶溶栓治疗急性心肌梗塞疗效比较

为总结我院两年来静脉溶栓治疗急性心肌梗塞（AMI）之临床经验。收集1994年2月以来，我院CCU接受静脉溶栓治疗的AMI患者共200例，其中用尿激酶（天普洛欣）119例，链激酶81例。结果：两组临床疗效，即血管再通率、5周病死率相近，两药同样安全、有效。副作用中，皮肤粘膜轻度出血率相近，但键激酶的一过性低血压为高（12．3％比0．84％，P＜0．001）。结论：两药治疗AMI同样安全有效。

Comparison of the efficacies of thrombolytic therapy on acute myocardial infarction between with urokinase and streptokinase

By comparing the efficacies of thrombolytic therapy on acute myocardial infarction (AMI)with streptokinase and urokinase,we observe their safety,efficacy and different characteristics of these two thrombolytic agents. Date were collected from our CCU ward since 1994 Feb.,which about the efficacy of venous thrombolytic therapy on 200 cases of AMI. They were similar for the rate of clinical vessel reperfusion and 5-week mortality,and both agents safe and effective. The rate fo mucocutaneous minor bleeding were not different significantly between two groups;while those of transient low blood pressure was higher in streptokinase group (12. 3% vs 0. 84%,P<0. 001). It is safe and effective for Chinese AMI cases to be treated by streptokinase or urokinase.